Alzheimer's dementia: Harvard University found that in people at genetic risk of dementia, there was a significant increase in the neurone-stranded protein

There is an urgent need for widely used and inexpensive Alzheimer's disease (AD) biomarkers that can be used in clinical trials to assess the efficacy of disease-improving drugs.
promising candidate is the Neuroseed Light Chain Protein (NfL), a sensitive marker of early neuron damage and shaft mutation that has been shown to rise in preclinical AD.
recently found significant increases in plasma NfL levels between normal chromosomal explicit AD (ADAD) relatives, who are more likely to develop early onset dementia.
blood plasma NfL levels in the ADAD mutation carrier and non-carrier family members subtly began to show a difference, the mutant carrier 22 years before the onset of clinical symptoms of the same relatives.
level of plasma NfL indicates a greater decline in cognitive ability in the preclinical stage of the disease.
these findings are consistent with those of the explicit genetic Alzheimer's Disease Network (DIAN), which reported that serum NfL levels can distinguish between carriers and non-carriers of mutations 7 to 16 years before the expected age of onset of clinical symptoms.
many studies have shown that blood-based NfL levels are sensitive to early neuron degeneration of ADAD.
cross-sectional studies have shown that higher plasma NfL levels are associated with increased hippocemia, thinning of the cortical layer, reduced thickness of the precuneus cortical layer, total brain volume, and reduced metabolism in these areas.
Similarly, longitudinal studies of familial and exudable ADs have shown that higher baseline NfL concentrations in the blood are associated with subsequent reduction rates of wedge presupposes, cortical thickness, rapid changes in white matter strength, and greater sugar metabolism and cognitive decline.
, of Harvard University, explored whether plasma NfL was associated with cognitive performance in amyloid β and tau, as well as in non-dementia presenilin-1 (PSEN1) E280A mutation carriers.
they included 25 mutant carriers and 19 non-carriers (age range: 28 to 49 years old).
participants were tested for 11C Pittsburgh compound B (PiB)-PET (evaluating A beta protein), fluorouracil-PET (evaluating tau), blood sampling, and cognitive testing.
showed that the plasma NfL level of the mutant carrier was higher than that of the non-carrier.
in carriers, higher NfL levels were associated with greater regional tau burden and poorer cognition, but not with β amyloid protein load.
when adjusting age, an important indicator of disease progression, elevated plasma NfL levels were associated only with poorer memory.
significance of this study is the discovery of a link between plasma NfL, cognition and tau pathology in non-dementia individuals with a genetic risk of AD dementia.
plasma NfL may help to select individuals at increased risk and track the progression of AD disease.
original origin: Guzmán-Vélez, E., Zetterberg, H., et al. Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease. _Alzheimer's & dementia: the journal of the Alzheimer's Association_. Freeman Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medical and are not reproduced by any media, website or individual without authorization, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here